Vanguard Group
ARCT icon

Vanguard Group’s Arcturus Therapeutics ARCT Stock Holding History

Vanguard Group’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$12.8M Buy
2,089,641
+204,036
+11% +$2.2M ﹤0.01% 2839
2025
Q3 		$34.8M Buy
1,885,605
+75,440
+4% +$1.21M ﹤0.01% 2334
2025
Q2 		$23.6M Buy
1,810,165
+61,237
+4% +$724K ﹤0.01% 2484
2025
Q1 		$18.5M Buy
1,748,928
+64,367
+4% +$1.02M ﹤0.01% 2538
2024
Q4 		$28.6M Buy
1,684,561
+107,635
+7% +$2.03M ﹤0.01% 2414
2024
Q3 		$36.6M Buy
1,576,926
+192,182
+14% +$4.11M ﹤0.01% 2313
2024
Q2 		$33.7M Sell
1,384,744
-3,150
-0.2% -$95.5K ﹤0.01% 2309
2024
Q1 		$46.9M Sell
1,387,894
-70,486
-5% -$2.5M ﹤0.01% 2202
2023
Q4 		$46M Buy
1,458,380
+51,537
+4% +$1.22M ﹤0.01% 2223
2023
Q3 		$35.9M Sell
1,406,843
-221,573
-14% -$6.83M ﹤0.01% 2285
2023
Q2 		$46.7M Buy
1,628,416
+163,070
+11% +$4.44M ﹤0.01% 2216
2023
Q1 		$35.1M Buy
1,465,346
+14,921
+1% +$268K ﹤0.01% 2340
2022
Q4 		$24.6M Buy
1,450,425
+113,607
+8% +$1.98M ﹤0.01% 2528
2022
Q3 		$19.8M Buy
1,336,818
+143,162
+12% +$2.4M ﹤0.01% 2627
2022
Q2 		$18.8M Buy
1,193,656
+40,143
+3% +$788K ﹤0.01% 2669
2022
Q1 		$31.1M Buy
1,153,513
+6,291
+0.5% +$161K ﹤0.01% 2545
2021
Q4 		$42.5M Buy
1,147,222
+33,271
+3% +$1.36M ﹤0.01% 2450
2021
Q3 		$53.2M Sell
1,113,951
-65,890
-6% -$2.95M ﹤0.01% 2326
2021
Q2 		$39.9M Sell
1,179,841
-17,539
-1% -$594K ﹤0.01% 2487
2021
Q1 		$49.5M Buy
1,197,380
+14,998
+1% +$894K ﹤0.01% 2324
2020
Q4 		$51.3M Buy
1,182,382
+145,205
+14% +$9.83M ﹤0.01% 2189
2020
Q3 		$44.5M Buy
1,037,177
+166,242
+19% +$8.25M ﹤0.01% 2074
2020
Q2 		$40.7M Buy
870,935
+727,354
+507% +$25.1M ﹤0.01% 2104
2020
Q1 		$1.95M Buy
143,581
+19,700
+16% +$252K ﹤0.01% 3321
2019
Q4 		$1.35M Hold
123,881
– – ﹤0.01% 3554
2019
Q3 		$1.27M Buy
+123,881
New +$1.34M ﹤0.01% 3579

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group's ARCT Position: Q4 2025 in Review

Vanguard Group increased its Arcturus Therapeutics (ARCT) stake by 11% in Q4 2025, buying an estimated $2.2M and bringing the position to 2,089,641 shares worth $12.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2839.

Vanguard Group first reported a position in ARCT in Q3 2019 and has held it in 26 quarters since. The position peaked at $53.2M in Q3 2021. 120 funds tracked by Wall St. Rank hold ARCT as of Q4 2025.

  • Vanguard Group held 2,089,641 shares of Arcturus Therapeutics worth $12.8M as of Q4 2025.
  • Vanguard Group bought 204,036 Arcturus Therapeutics shares in Q4 2025, an estimated $2.2M.
  • Arcturus Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2839 holding.
  • Vanguard Group first reported a position in Arcturus Therapeutics in Q3 2019 and has held it in 26 quarters since.
  • Vanguard Group's Arcturus Therapeutics position peaked at $53.2M in Q3 2021.
  • 120 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.